Stocks of Xerox Holdings Corp (NASDAQ:XRX) traded higher last session on Wall Street, down -10.83% to $5.93.
XRX stock price is now 11.77% away from the 50-day moving average and -15.54% away from the 200-day moving average. The market capitalization of the company currently stands at $745.93M.
With the price target of $11, Citigroup recently initiated with Sell rating for Xerox Holdings Corp (NASDAQ: XRX). On August 17, 2022, Credit Suisse recently initiated its ‘Underperform’ rating on the stock quoting a target price of $14, while ‘Morgan Stanley’ rates the stock as ‘Underweight’
In other news, BRUNO JOHN G, President and COO bought 25,000 shares of the company’s stock on May 23 ’25. The stock was bought for $109,500 at an average price of $4.38. Upon completion of the transaction, the President and COO now directly owns 259,775 shares in the company, valued at $1.54 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 23 ’25, CEO BANDROWCZAK STEVEN JOHN bought 22,300 shares of the business’s stock. A total of $99,904 was incurred on buying the stock at an average price of $4.48. This leaves the insider owning 382,442 shares of the company worth $2.27 million. A total of 7.64% of the company’s stock is owned by insiders.
During the past 12 months, Xerox Holdings Corp has had a low of $3.44 and a high of $12.04. As of last week, the company has a debt-to-equity ratio of 2.77, a current ratio of 1.09, and a quick ratio of 0.77. The fifty day moving average price for XRX is $5.3058 and a two-hundred day moving average price translates $7.0209 for the stock.
The latest earnings results from Xerox Holdings Corp (NASDAQ: XRX) was released for 2025-03-31. The net profit margin was -21.24% and return on equity was -67.27% for XRX. The company reported revenue of $1.46 billion for the quarter, compared to $1.5 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -3.0 percent. For the current quarter, analysts expect XRX to generate $1.55B in revenue.
